Display options
Cite
Repana D, Ross P. Targeting FGF19/FGFR4 Pathway: A Novel Therapeutic Strategy for Hepatocellular Carcinoma. Diseases. 2015;3(4):294-305doi: 10.3390/diseases3040294.
Repana, D., & Ross, P. (2015). Targeting FGF19/FGFR4 Pathway: A Novel Therapeutic Strategy for Hepatocellular Carcinoma. Diseases (Basel, Switzerland), 3(4), 294-305. https://doi.org/10.3390/diseases3040294
Repana, Dimitra, and Ross, Paul. "Targeting FGF19/FGFR4 Pathway: A Novel Therapeutic Strategy for Hepatocellular Carcinoma." Diseases (Basel, Switzerland) vol. 3,4 (2015): 294-305. doi: https://doi.org/10.3390/diseases3040294
Repana D, Ross P. Targeting FGF19/FGFR4 Pathway: A Novel Therapeutic Strategy for Hepatocellular Carcinoma. Diseases. 2015 Oct 28;3(4):294-305. doi: 10.3390/diseases3040294. PMID: 28943626; PMCID: PMC5548263.
Copy Download .nbib Format: NLM
Share it on

Diseases. 2015 Oct 28;3(4):294-305. doi: 10.3390/diseases3040294.

Targeting FGF19/FGFR4 Pathway: A Novel Therapeutic Strategy for Hepatocellular Carcinoma.

Diseases (Basel, Switzerland)

Dimitra Repana, Paul Ross

Affiliations

  1. Department of Medical Oncology, Guy's and St. Thomas' NHS Foundation Trust, SE1 9RT London, UK. [email protected].
  2. Department of Medical Oncology, Guy's and St. Thomas' NHS Foundation Trust, SE1 9RT London, UK. [email protected].
  3. Department of Oncology, King's College Hospital, SE19 1RT London, UK. [email protected].

PMID: 28943626 PMCID: PMC5548263 DOI: 10.3390/diseases3040294

Abstract

Hepatocellular carcinoma (HCC) is a lethal cancer with limited systemic therapeutic options. Liver carcinogenesis is a complex procedure and various pathways have been found to be deregulated which are potential targets for novel treatments. Aberrant signalling through FGF19 and its receptor FGFR4 seems to be the oncogenic driver for a subset of HCCs and is associated with poor prognosis. Inhibition of the pathway in preclinical models has shown antitumour activity and has triggered further evaluation of this strategy to

Keywords: FGF19; FGFR4; hepatocellular carcinoma; β-Klotho

References

  1. J Clin Oncol. 2013 Oct 1;31(28):3509-16 - PubMed
  2. J Biol Chem. 2007 Sep 14;282(37):27277-84 - PubMed
  3. Int J Cancer. 2004 Aug 20;111(2):213-7 - PubMed
  4. Cold Spring Harb Symp Quant Biol. 2011;76:139-44 - PubMed
  5. J Biol Chem. 1999 May 28;274(22):15947-52 - PubMed
  6. J Hepatol. 2009 Jan;50(1):118-27 - PubMed
  7. PLoS One. 2012;7(5):e36713 - PubMed
  8. Am J Pathol. 2002 Jun;160(6):2295-307 - PubMed
  9. Mol Cancer Ther. 2011 Nov;10(11):2200-10 - PubMed
  10. Mol Cancer. 2012 Mar 23;11:14 - PubMed
  11. Cancer Cell. 2011 Mar 8;19(3):347-58 - PubMed
  12. Cancer Discov. 2012 Dec;2(12):1118-33 - PubMed
  13. Toxicol Sci. 2012 Apr;126(2):446-56 - PubMed
  14. Dig Dis Sci. 2013 Jul;58(7):1916-22 - PubMed
  15. Gut. 2013 Jun;62(6):899-910 - PubMed
  16. Clin Cancer Res. 2004 Sep 15;10(18 Pt 1):6169-78 - PubMed
  17. Clin Cancer Res. 2015 Jun 15;21(12):2684-94 - PubMed
  18. Drugs. 2015 Jan;75(1):129-39 - PubMed
  19. Clin Liver Dis. 2015 May;19(2):361-79 - PubMed
  20. Cancer Discov. 2015 Apr;5(4):424-37 - PubMed
  21. N Engl J Med. 2008 Jul 24;359(4):378-90 - PubMed
  22. J Clin Oncol. 2013 Oct 1;31(28):3517-24 - PubMed
  23. J Hepatol. 2010 Jun;52(6):921-9 - PubMed
  24. Liver Int. 2014 Jul;34(6):e1-9 - PubMed
  25. Liver Cancer. 2012 Sep;1(2):83-93 - PubMed
  26. Nat Rev Cancer. 2006 Sep;6(9):674-87 - PubMed
  27. Cancer Res. 2012 Apr 15;72(8):2045-56 - PubMed
  28. Proc Natl Acad Sci U S A. 2014 Nov 11;111(45):E4869-77 - PubMed
  29. JAMA. 2015 Jun 9;313(22):2263-73 - PubMed
  30. Wiley Interdiscip Rev Dev Biol. 2015 May-Jun;4(3):215-66 - PubMed
  31. J Proteome Res. 2015 Sep 4;14(9):3670-9 - PubMed
  32. Lancet Oncol. 2009 Jan;10(1):25-34 - PubMed
  33. Hepatology. 2014 Dec;60(6):1972-82 - PubMed
  34. J Hepatol. 2006 Oct;45(4):529-38 - PubMed
  35. BMC Cancer. 2012 Feb 06;12:56 - PubMed
  36. Dig Dis Sci. 1991 Jul;36(7):962-72 - PubMed
  37. Med Res Rev. 2014 Mar;34(2):280-300 - PubMed
  38. Int J Med Sci. 2013 Nov 12;10(13):1868-75 - PubMed
  39. Clin Cancer Res. 2012 Apr 1;18(7):2090-8 - PubMed
  40. Int J Cancer. 2015 May 15;136(10):2469-75 - PubMed
  41. Expert Opin Ther Targets. 2015 May;19(5):675-85 - PubMed
  42. Exp Mol Pathol. 2007 Feb;82(1):53-7 - PubMed
  43. Nat Rev Drug Discov. 2009 Mar;8(3):235-53 - PubMed
  44. World J Hepatol. 2015 May 28;7(9):1157-67 - PubMed
  45. Oncogene. 2008 Jan 3;27(1):85-97 - PubMed
  46. J Biochem. 2011 Feb;149(2):121-30 - PubMed
  47. Endocrinology. 2002 May;143(5):1741-7 - PubMed
  48. N Engl J Med. 2011 Sep 22;365(12):1118-27 - PubMed
  49. J Hepatol. 2012 Apr;56(4):908-43 - PubMed
  50. Carcinogenesis. 2014 Oct;35(10):2331-8 - PubMed
  51. Mol Cell Biol. 2007 May;27(9):3417-28 - PubMed

Publication Types